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The matrix domain of the Gag precursor protein, and the mature matrix protein, which is derived from processing of the
Gag precursor, functions in several steps of the human immunodeficiency virus type-1 (HIV-1) life cycle. We made numerous
mutations throughout the matrix protein and identified three mutants in the N-terminal portion of the matrix that drastically
diminish the ability of the virus to replicate. Each of these replication-defective mutants was unable to acquire efficiently
the envelope glycoprotein of HIV-1. To determine whether these same mutations affect other steps in viral replication we
pseudotyped mutant particles with the envelope glycoprotein from an amphotropic murine leukemia virus. Each of these
mutants was also hampered in other steps in virus replication. Two mutants were defective in entry or uncoating, and the
third was hampered in a step following reverse transcription. Since viral replication was analyzed under conditions in which
the nuclear localization function of the matrix protein is not required, the matrix protein may be required for an additional
replication step following reverse transcription. q 1997 Academic Press
INTRODUCTION cleaved by the viral protease and maturation of the parti-
cle occurs (Katoh et al., 1985).
The gag gene of HIV-1 encodes a polyprotein precur-
The MA domain of Pr55 contains signals necessarysor (Pr55) that is cleaved by the viral protease into mature
for the correct targeting of Gag to the plasma membrane.viral proteins termed matrix p17(MA), capsid P24 (CA),
MA of almost all retroviruses, including spleen necrosisnucleocapsid p7(NC), p6, and two smaller proteins p2
virus, murine leukemia virus, and HIV, is myristoylatedand p1 (Leis et al. 1988; Mervis et al., 1988; Henderson
at the N-terminal glycine residue (Katoh et al., 1985;et al., 1992). The expression of Gag, in the absence of
Mervis et al., 1988; Veronese et al., 1988; Weaver andother viral proteins, results in particle formation (Kawai
Panganiban, 1990). This posttranslational modificationand Hanafusa, 1973; Gheysen et al., 1989; Karacostas et
contributes significantly to the hydrophobic character ofal., 1989; Rhee et al., 1990; Smith et al., 1990), indicating
MA. If myristoylation is prevented by mutation, the re-that Gag contains all the necessary information for parti-
sulting gag precursors are no longer able to stably asso-cle assembly. Two events that are necessary for particle
ciate with the plasma membrane or assemble into parti-formation are correct targeting of Gag to the plasma
cles (Rein et al., 1986; Rhee and Hunter, 1987; Gottlingermembrane and intermolecular association of multiple
et al., 1989; Bryant and Ratner, 1990; Weaver andGag precursors into the nascent core.
Panganiban, 1990). In addition to myristoylation, the firstThere are two major alternative pathways for particle
33 amino acid residues of HIV-1 MA are of an overallassembly in retroviruses. The type B and D retroviruses
basic nature and have been proposed to interact withassemble their particles in the cytoplasm of the infected
acidic phospholipids at the plasma membrane, thus facil-cell (Coffin, 1990). These particles are transported to the
itating a stronger Gag–membrane interaction (Zhou etplasma membrane where budding and acquisition of the
al., 1994). There are still other signals in MA required forviral envelope occur. Lentiviruses, including human im-
differential targeting of the precursor to either intracellu-munodeficiency virus type one (HIV-1), and type C retrovi-
lar membranes or the cell surface. In Mason–Pfizer mon-ruses assemble their particles by a different mechanism.
key virus a single amino acid change in MA changes theThe gag polyprotein precursor (Gag) is inserted into the
assembly of this type D pattern to a type C pattern ofplasma membrane and forms immature cores concurrent
budding (Rhee and Hunter, 1990). Further, several muta-with envelopment by the plasma membrane (Feller et al.,
tions in HIV-1 MA appear to redirect the site of assembly1971; Dalton, 1972; Gelderblom et al., 1987). Gag is then
to intracellular membranes (Gelderblom et al., 1987;
Facke et al., 1993; Yuan et al., 1993; Spearman et al.,
1 Present address: National Jewish Center, Goodman Building, 1400 1994). Several mutations also reduce the level of virusJackson Street, Denver, CO 80206.
particle production (Yu et al., 1992; Yuan et al., 1993;2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (608) 262-2824. E-mail: panganiban@oncology.wisc.edu. Dorfman et al., 1994; Spearman et al., 1994).
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In addition to domains that function in membrane local- tant of cell debris. CD4-LTR/b-gal indicator cells, seeded
at 4 1 104 cells per well on a 24-well plate, were infectedization, the matrix protein of HIV-1 contains a nuclear
localization signal that allows HIV-1 to replicate in nondi- by exposure to serially diluted culture supernatants in
200 ml culture medium containing 8 mg/ml DEAE Dextranviding cells (Bukrinsky et al., 1993; Heinzinger et al., 1994;
von Schwedler et al., 1994). This ability appears to be for 2 hr. After this adsorption period, culture medium was
added to each well. Infection was measured by scoringunique to lentiviruses (Haase, 1975; Harel et al., 1981;
Chen and Temin, 1982). The nuclear localization signal Tat-inducible b-gal expression 2 days later, as described
previously (Kimpton and Emerman, 1992).of HIV-1 appears to be redundant since a nuclear local-
ization signal is also found in Vpr, an accessory protein
of HIV-1 that is found in the virion (Paxton et al., 1993; DNA constructs
Heinzinger et al., 1994; Lavallee et al., 1994). In MA mu-
tants, Vpr can partially compensate for a defect in the Matrix mutations were made by site-directed mutagen-
esis as described (Kunkel et al., 1987) using a subcloneMA nuclear localization signal. However, both signals
appear to be required for maximally efficient replication of the NL4-3 provirus (Adachi et al., 1986). Several mu-
tants were made by using degenerate oligonucleotidesin nondividing cells (Heinzinger et al., 1994). MA of HIV-
1 has also been found in preintegration complexes corresponding to different regions of the matrix gene.
Oligonucleotides ‘‘gaa aca atg taa act,’’ ‘‘caa tat aaa cta(Bukrinsky et al., 1992; Karageorgos et al., 1993; Hein-
zinger et al., 1994). However, it is not clear whether the ata ctt ata gta tgg,’’ ‘‘tgg gaa ata att ggg tta gcg cag gg,’’
‘‘gaa aag gaa caa tat,’’ and ‘‘caa agg ata gct gta ata’’ wereMA protein is located there solely to direct the integration
complex into the nucleus of nondividing cells or whether used to make mutations MA29, MA32,33, M18,20,22,
MA27, and MA93,95, respectively. The mutations wereit serves a more direct role in integration.
Further functions attributed to the matrix protein in- introduced into GB107 (Buchschacher and Panganiban,
1992) using the unique restriction sites BssHII (nucleo-clude a role in an early step in virus entry (Yu et al., 1992)
and a role in efficient acquisition of envelope glycopro- tide 715) and SpeI (nucleotide 1507). GB107 is derived
from pNL4-3 and has a deletion in the envelope genetein by budding particles (Yu et al., 1992; Wang et al.,
1993; Dorfman et al., 1994). We investigated several mu- spanning the restriction sites StuI and NheI. The mutant
constructs were verified by sequence analysis.tations in HIV-1 MA, identified several that drastically
reduce infectivity, and identified the steps in replication The clone Pr-Dbal was constructed in several steps.
First, a BalI deletion of GB107 (see above) was createdthat are affected by the mutations using quantitative
assays. These replication-defective mutants were pleio- to delete sequences between nucleotides 2621 and
4553. An ApaI to SalI fragment containing sequencestropic. In addition to deficiencies in incorporation of Env-
gp into particles, the mutants were either deficient in a corresponding to the deleted sequences was then intro-
duced into pGemNL43Dpol (kindly provided by M. Scottstep immediately following virus entry into cells or defi-
cient in a step following reverse transcription. McBride) (pGemNL43Dpol contains the NL4-3 pro-
virus introduced into the polylinker site of pGEM11ZF-
(Promega)). The resulting plasmid was designatedMATERIALS AND METHODS
pNL43Dbal. MS172 (kindly provided by Michael
Cell culture, transfections, and infections
Schwartz) contains an asparagine-to-arginine mutation
at amino acid residue 25 of the viral protease. A SpeI toHeLa, HeLa T4, and CD4-LTR/b-gal (Kimpton and
Emerman, 1992) indicator cells were cultured in Dulbec- BalI fragment containing this mutation was introduced
into pNL43Dbal. The resulting clone was called Pr-Dbal.co’s modified Eagle’s medium containing penicillin G so-
dium, streptomycin sulfate, 10 mM HEPES (Gibco), and The matrix mutations were cloned into this construct us-
ing the unique sites BssHII and SpeI.7% calf serum. HeLa T4 cells were periodically cultured
in 600 mg/ml G418 (Gibco) to select for expression of CC91, which was used as the competitor in the quanti-
tative competitor PCR reaction, was also created in sev-CD4. CD4-LTR/b-gal indicator cells were cultured under
selection with 100 mg/ml Hygromycin B (Gibco) and 400 eral steps. pMSMBA (kindly provided by M. Scott
McBride) is proviral, containing a deletion in the envelopemg/ml G418. Cells were seeded at 4 1 105 to 5 1 105
cells per 60-mm dish or at 1 1 106 to 1.5 1 106 cells per gene. In addition, pMSMBA is a carried in pGEM11ZF0
rather than the original NL4-3 vector. The 3* LTR of100-mm dish and then were transfected 1 day later by
the calcium phosphate coprecipitation method (Harel et pMSMBA was removed by creating a deletion between
the EcoRI site in the viral sequence and a second oneal., 1981). Cells in 60- or 100-mm dishes were transfected
with a total of 10 or 20 mg DNA, respectively, at a 1:1 distal to the 3* LTR. A deletion was then made in the 5*
LTR using the polymerase chain reaction (PCR) as fol-ratio of viral:envelope DNA (see below). To isolate virus
for infection, media were harvested 72 hr after transfec- lows. A primer pair corresponding to nucleotides 272–
298 (cct agc att tcg tca cat ggc ccg) and nucleotides 522–tion and centrifuged at low speed to clear the superna-
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549 (gag cac tca agg cac gcg tta ttg agg c) (containing a enhanced chemiluminescence (ECL) (Amersham) was
used in Western analysis, the secondary antibody wasMluI restriction site) and a primer pair corresponding to
nucleotides 560–583 (gtg ccc gtc tga cgg gtg act ctg) goat anti-human (Sigma) at a dilution of 1:5000 followed
by tertiary rabbit anti-goat antibody conjugated with(containing a MulI restriction site) and nucleotides 739–
764 (aaa att ttt ggt gca cta acc agt c) were used to horseradish peroxidase (Sigma) at a dilution of 1:10,000.
To obtain radioactive Western blots for phosphorimageamplify the sequences contained within the LTR. The
resulting fragments were cut with MluI and ligated to analysis, the secondary rabbit anti-human antibody was
used at a dilution of 1:5000 (Sigma) and 35S-labeled don-create a 41-basepair deletion spanning part of R and U5
in the LTR. This fragment containing the deletion was key anti-rabbit antibody (Amersham) was used as a ter-
tiary antibody at a concentration of 0.2 mCi/ml. To detectthen placed into the 5* LTR of CC91 using the restriction
sites BspEI (nucleotide 308) and BssHII (nucleotide 715). amphotropic envelope glycoprotein we used the primary
goat anti-gp70 antibody (kindly provided by Eric Barklis)The envelope glycoprotein expression construct CC60
contains the KpnI (nucleotide 6345) to XhoI (nucleotide at a 1:5000 dilution, followed by rabbit anti-goat antibody
(a 1:5000 dilution), followed by goat anti-rabbit antibody8870) of NL4-3 cloned into pBG139 (Geraghty and
Panganiban, 1993). pBG139 contains the Tat-inducible conjugated with horseradish peroxidase (Sigma) (a dilu-
tion of 1:10,000), followed by ECL.HIV-1 promoter enhancer and expresses Env, Vpu, and
Rev. Plasmid HcenvSV (Kim and Risser 1993) contains
RNA analysisthe human cytomegalovirus immediate early enhancer
promoter and expresses the env gene of the HIV-1 strain
Virus was pelleted and equal numbers of physical par-
HXB2. SV-A-MuLV was kindly provided by Dan Littman
ticles, as determined by p24 ELISA (see above), were
(Page et al., 1990) and contains the simian virus 40 imme-
used to isolate RNA. Particles were incubated in 6% su-
diate early enhancer promoter followed by the murine
crose, 0.25% NP-40, 10 mM MgCl2 , 10 mM CaCl2 , 150leukemia virus (MuLV) enhancer and the amphotropic
units micrococcal nuclease, and 150 units DNase I
MuLV env gene.
(Boehringer Mannheim) for 30 min at 377 to remove nu-
cleic acid outside the capsid. Then 1% SDS and 0.6 mg/
Protein analysis ml proteinase K were added and the sample was incu-
bated a further 30 min at 377. The samples were extracted
Viral particles were obtained by filtering culture super-
in phenol–chloroform several times and precipitated in
natants from transfected cells in three 100-mm plates
ethanol in the presence of 10 mg carrier poly(C). One half
through a 0.2-mm filter. The supernatant was then layered
of the sample was resuspended in 20 mM Tris–HCl; 10
over a 10-ml cushion of 20% sucrose in STE (100 mM
units of RNase was added (Boehringer Mannheim) and
NaCl, 10 mM Tris–HCl, pH 7.4, and 1 mM EDTA) con-
the sample was incubated at 377 for 30 min. Both the
taining 2 mg/ml aprotonin and centrifuged for 2.5–3 hr
untreated and the RNase-treated samples were added
in a SW28 rotor at 58,000 g. Pelleted particles were re-
to a solution of 50% formamide, 7% formaldehyde, 11
suspended in STE. The number of physical particles was
SSC (150 mM NaCl, 15 mM sodium citrate dihydrate),
determined using a capsid p24 antigen enzyme-linked
heated at 687 for 15 min, and placed on ice for 5 min,
immunosorbent assay (ELISA) kit (Coulter, Inc., Healea,
and 2 vol of 201 SSC was added. The samples were
FL). In each experiment a standard curve was generated
loaded onto a slot blot apparatus and the RNA detection
by making serial dilutions of p24 provided with the kit.
was performed as described in Molecular Cloning: A
Cell lysates were collected by washing transfected
Laboratory Manual (Sambrook et al., 1989). The probe
cells twice in phosphate-buffered saline (PBS) and re-
used for hybridization was radiolabeled using the Ran-
moving them from the tissue culture plates using PBS
dom Primed DNA Labeling Kit from Boehringer Mann-
supplemented with 10 mM EDTA. The harvested cells
heim. The fragment used for the probe was from the pol
were washed twice in PBS, lysed in IP buffer (20 mM
gene (nucleotides 2621 to 4553).
Tris–HCl, pH 7.5, 150 mM NaCl, 1.0 mM EDTA, 0.1%
SDS, 0.5% sodium deoxycholate, 1.0% Triton X-100, 0.02% Entry assay
sodium azide), and then centrifuged to remove cellular
debris. Virus (between 0.3 and 3 ng CA units as determined
by a p24 ELISA) was diluted into 85 ml of STE (100 mMWestern blots were performed by resolving proteins
from cell lysates or viral pellets using sodium dodecyl NaCl, 10 mM Tris–HCl, pH 7.4, 1 mM EDTA); 10 ml 100
mM MgCl2 and 5 ml DNase (Boehringer Mannheim 10sulfate (SDS)–polyacrylamide gel electrophoresis and
electrotransferred to nitrocellulose membranes (Towbin units/ml) were added, and the mixture was incubated at
377 for 30 min. The virus was then added to the HeLaet al., 1979). Each membrane was blocked in 5% dry
milk dissolved in PBS. For HIV-1 protein recognition AIDS T4 cells (seeded at 5 1 105 per 60-mm dish the day
before) in a volume of 0.5 ml medium containing 8 mg/patient serum was used as the primary antibody. When
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ml DEAE dextran. The virus was allowed to adsorb to of mutants in different regions of the MA-coding region
of gag we carried out site-directed mutagenesis usingthe cells in this volume at 377 for 2 hr with occasional
rocking. Four milliliters of medium was then layered onto degenerate oligonucleotides. We then selected 11 mu-
tants containing lesions distributed throughout this seg-the cells and the incubation continued for an additional
6 hr. Medium was then removed from the cells and the ment of the genome (Fig. 1A), and tried to identify muta-
tions that profoundly affect replication. The MA mutationscells were washed twice in phosphate-buffered saline
(PBS) containing 2 mM EDTA. Trypsin (1.5 ml) was then were introduced into a HIV-1 DNA construct (GB107)
(Buchschacher and Panganiban, 1992) that contains aadded at a concentration of 0.5 mg/ml (Sigma) and the
cells were incubated for 7–10 min. The cells were next deletion in the envelope gene, leaving all other HIV-1
genes unaffected (Fig. 1B). Wild-type or mutant con-added to a tube containing 9 ml of medium and centri-
fuged, and the pellet was washed twice in PBS. The cell structs were then transfected into HeLa cells along with
an HIV-1 envelope expression vector (CC60 or HcenvSV)pellet was resuspended in 100 ml lysis buffer (0.5% NP-
40, 50 mM KCl, 10 mM Tris–HCl, pH 8.3) and 0.7 mg/ml (Fig. 1B). Three days later virus was collected from the
transfected cells and used to infect CD4/ LTR/b-gal indi-proteinase K (Boehringer Mannheim), heated at 657 for
30 min and then heated at 957 for 10 min. This sample cator cells. This latter cell line is a HeLa cell derivative
that expresses CD4 and contains a copy of the lac-zwas then used as a template for PCR. Three negative
controls were used in the entry assay. First, medium gene under transcriptional control of the HIV-1 LTR
(Kimpton and Emerman, 1992). Upon successful infectionfrom mock-transfected cells was prepared and tested in
parallel with transfected cells. Second, GB107 particles of the CD4/ LTR/b-gal indicator cells, Tat protein ex-
pressed from the provirus that arises from the infectionlacking Env were generated and presented to cells. Fi-
nally, GB107 particles containing Env were applied to transactivates the endogenous HIV-1 LTR, leading to ex-
pression of the lac-z gene. Infected cells can then becells for 1 hr, on ice, to allow virus–cell interaction to
occur without subsequent entry of virus into cells. identified by staining with 5-bromo-4-chloro-3-indoly-b-
D-galactopyranoside and the titer of the infecting virusQuantitative competitive-PCR (QC-PCR) as described
in Piatak et al. (1993) was performed on the cell lysates. can be calculated. Since the infecting virus packages the
viral RNA expressed from GB107 (or derivatives of GB107Briefly, the amount of template is kept constant in each
reaction while the amount of competitor DNA containing (or derivatives of GB107 harboring mutations in MA) no
envelope will be expressed in the infected cells and noa deletion within the region of amplification was added to
the reaction at known concentrations. The PCR products further virus propagation can occur. In this way it was
possible to accurately measure the replication pheno-were separated on a gel and the amount of each product
was determined by phosphorimage analysis. Compari- type of the MA mutants relative to wild-type virus over a
single cycle of replication. Most mutants had little effectson of the amounts of the amplification products allowed
us to determine the approximate relative amounts of on replication but mutations MA18,20,22, MA26,29, and
MA32,33 were markedly reduced in infectivity to £0.4,products from viral reverse transcription that arose fol-
lowing infection. Two to four microliters of the cell lysate 1, and £0.1%, respectively, when compared to wild-type
virus (Table 1). While both mutants MA26,29 andwas used in 50-ml reactions containing 1.25 mM MgCl2 ,
50 mM KCl, 10 mM Tris–HCl, pH 8.3, 200 mM dNTP’s, MA26,30 contained the same mutation at position 26,
their replication efficiencies were 1 and 40% of replica-0.25 ml AmpliTaq (reagents supplied by Perkin–Elmer
Cetus), 0.25 mM each primer, and 1.25 mCi of 5*-a-35S- tion efficiency, respectively (Table 1). Thus, it seemed
likely that the depression in infectivity of MA26,29 coulddATP (Amersham). The primers used were R nucleotides
488–511 ‘‘agc tct ctg gct aac tag gga acc,’’ U5 nucleotides be explained by the mutation at codon 29. We tested this
directly by making a single mutation in the 29th amino598–622 ‘‘tcc aca ctg act aaa agg gtc tga g,’’ and anti-
leader nucleotides 656–679 ‘‘tcc tct ggc ttt act ttc gct ttc.’’ acid residue in an otherwise wild-type background
(MA29). This mutant was reduced in infectivity to aboutPCR conditions used for the R–U5 primer pair were 1
min at 957, 1 min at 587, and 1 min at 727 for 35 cycles 3% of wild type, indicating that the replication-defective
phenotype of MA26,29 was due to the mutation in aminofollowed by 10 min at 727. The R-leader pair was essen-
tially the same except that the annealing temperature acid residue 29.
We next wanted to identify the steps in replication thatwas 547 and amplification was for 40 cycles.
were affected by the mutations in MA18,20,22, MA29,
and MA32,33 and that could account for their severeRESULTS
replication-defective phenotype. Since the matrix protein
is part of the Gag polyprotein precursor it was necessaryWe initially set out to study the role of the matrix do-
main of Gag in particle formation and release. However, to determine whether the mutations affected the expres-
sion and steady state level of Gag. To measure steadywe were cognizant of the fact that the MA peptide has
multiple functions in virus replication. To obtain a battery state protein levels, cell lysates were collected following
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analysis of the gel and comparison to the standard curve
generated by loading serial twofold dilutions of wild-type
protein (Fig. 2B). Examination of Fig. 2A also indicated
that for each of the mutants there was slight accumula-
tion of a processing intermediate of CA (p25). P25 is
cleaved by the viral protease into p24 and p2 (Henderson
et al., 1992). Quantitation of the immunoblot indicated
that wild-type virus had a 10:1 level of p24:p25 while
MA18,20,22 and MA32,33 had a 3:1 ratio and mutant
MA29 had 1 5:1 p24:p25 ratio. A similar accumulation
of p25 for deletion mutants in MA has been previously
reported (Yu et al., 1992) and likely indicates a marginal
processing defect in the matrix mutants.
To determine whether the mutations in MA signifi-
cantly reduce the level of virus production cells were
transfected with DNA expressing wild-type or mutant vi-
ral protein and particles were isolated. The amount of
pelleted virus was then quantified using an antigen-cap-
ture assay specific for p24 (Table 2). This analysis indi-
cated that MA29 was not reduced in virus production but
that the MA18,20,22 and MA32,33 mutants were reduced
to about 20% of wild type. Although some of the observed
reduction in infectivity of these two mutants might be due
to this reduced level of virus production, we thought it
unlikely that this reduction could fully account for the
profound decrease in viral infectivity.
Recent evidence suggests that even a slight reduction
in processing of the Gag precursor in the virion can re-
FIG. 1. HIV-1 MA mutants and expression constructs. (A) Location duce infectivity significantly (Schatzl et al., 1991; Kaplan
of MA secondary structure features (Matthews et al., 1994) and MA et al., 1993) and, based on the analysis of intracellular
mutations. Gag and encoded viral proteins are indicated. Black boxes
represent the location of three b-sheets (residues 19–23, 26–29, and
94–97) that are predicted to form an irregular mixed b-sheet. The coils
TABLE 1represent the location of four predicted helices (residues 33–45, 55–
69, 73–88, and 97–109). Number designations indicate the amino
Infectivity of Matrix Mutants
acid(s) that was mutated. The letters preceding the arrow indicate the
identity of the amino acids in the wild-type protein and those following
Virus Na Relative titer b { SD
the arrow indicate the amino acid in the mutant. For example, the
MA18,20,22 mutant has the 18th, 20th, and 22nd amino acids changed
GB107 23 100 { 23
from K, R, and R to I, G, and A, respectively. (B) HIV-1 expression
MA18,20,22 11 0.4 { 0.6
constructs. GB107 (Buchschacher and Panganiban, 1992) is derived
MA26,29 3 1.3 { 0.8
from the proviral construct pNL4-3 (Adachi et al., 1986) and contains
MA26,30 5 42 { 44
a deletion from the StuI to the NheI site in env. The plasmid Pr0Dbal
MA27 2 41 { 16
contains a deletion in the polymerase gene that encompasses most
MA29 10 2.7 { 4.5
of the reverse transcriptase and the 5* portion of the integrase coding
MA32,33 9 0.1 { 0.09
sequences. The plasmid CC60 expresses HIV-1 env and rev genes
MA72 4 120 { 95
from the HIV-1 promoter–enhancer and contains the simian virus 40
MA74 3 73 { 43
poly(A) signal. The plasmid HcenvSV (Page et al., 1990) expresses the
MA81 7 14 { 10
HIV-1 envelope gene from the human cytomegalovirus immediate early
MA90 2 80 { 80
enhancer and promoter (HCMV) and contains the simian virus 40
MA84,93,95 1 88 { 21
poly(A) signal. SV-A-MuLV-env (Page et al., 1990) expresses the ampho-
tropic envelope gene from the MuLV LTR and contains the simian virus a N denotes the number of experiments.
40 (SV) enhancer–promoter and simian virus 40 poly(A) signal. b The titer of the virus was determined by infection of CD4/ LTR/b-
gal indicator cells as described in the text. The titer of the wild-type
transcomplemented virus varied between experiments but was be-transfection of HeLa cells and analyzed by Western blot
tween 2 1 103 and 4 1 104 b-gal inducing units per milliliter. Controlsanalysis with serum from an AIDS patient (Fig. 2A). The
from mock-infected cells, medium from cells transfected with only the
level of both steady state Gag precursor protein (Pr55) env expression plasmid, or vectors in the absence of Env yielded negli-
and CA protein (p24) for all three mutants was 20–30% gible b-gal-positive cells. In most experiments the transfections and
infections were both performed in duplicate.compared to wild type, as determined by phosphorimage
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FIG. 2. Intracellular expression of viral protein from replication-defec-
tive MA mutants. (A) Cell lysates were collected and immunoblotted
as described under Materials and Methods. Equal amounts of cell
lysate were loaded in the lanes designated Mock, MA32,33,
MA18,20,22, and MA29, and in the GB107 lane marked 11. The GB107
lysates were also loaded in serial twofold dilutions as indicated. The FIG. 3. Analysis of Gag processing in MA mutant particles. (A) Viral
locations of Gag (Pr55) and the cleavage products p25 and p24 are particles were immunoblotted using serum from an AIDS patient as
indicated by arrows. (B) Relative expression of Gag Pr55 and CA p24 described under Materials and Methods and detected using a 35S-
in transfected cells. The data from three separate experiments were labeled antibody. The matrix mutants and mock lanes are as indicated.
analyzed and the relative amounts of Pr55 and p24 were measured Wild-type virus (GB107) was loaded in serial twofold dilutions as in
using a phosphorimager. In each experiment a standard curve for mea- Fig. 2. The gag precursor (Pr55) and the cleavage product p24 (CA)
suring Pr55 and p24 was created by serial twofold dilutions of cell are indicated by arrows. (B) Viral processing was quantified using
lysates from GB107; the amount of Pr55 and p24 was normalized to Western blots of virions. Wild-type virus was loaded in serial twofold
100% for GB107 in samples in which equal cell equivalents for the dilutions to generate a standard curve for the precursor (Pr55) and a
mutants and wild type were loaded. Intracellular levels of Pr55 (black) Gag cleavage product (p24). The mutant viruses were compared to
and p24 (shaded) are indicated. the standard curve and the relative amounts of Pr55 and p24 were
determined. The values represent the average of three experiments.
mutant Gag protein (Fig. 2A), it appeared that processing
to generate p24 might be slightly hampered. In light of ing the relative level of precursor and p24 in viral pellets
these observations we decided to determine whether using Western analysis and phosphorimaging (Fig. 3).
processing of the Gag precursor was efficient by measur- This analysis revealed that MA29 is not deficient in pro-
cessing while MA32,33 and MA18,20,22 are slightly re-
TABLE 2 duced in the ability to process Pr55 to p24 (Fig. 3B). This
reduction in processing indicates that the mutations mayRelative Virus Production for MA Mutants
indirectly affect the conformation of the p55 gag precur-
Relative virion sor, resulting in less efficient proteolytic processing.
Virus production { SDa Thus, it is possible that the reduced processing of
MA18,20,22 and MA32,33 may have reduced their infec-GB107 100
tivity.MA18,20,22 23 { 19
MA29 99 { 55 It was formally possible that the particles produced
MA32,33 23 { 20 from the mutants lacked MA as a result of decreased
protein stability after cleavage from the precursor or as aa Virion production was measured by pelleting filtered viral superna-
result of the inability of mutant MA to join the assemblingtants through a 20% sucrose cushion and performing a p24 ELISA
particle when processing occurs prior to particle release.assay on the resulting pellets. p24 units were normalized to wild type
in each experiment. The values represent at least nine experiments. To examine these possibilities directly an immunoblot
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background. The Pr0 mutant (Pr0 Dbal) has an amino
acid substitution in the active site of protease and also
contains a large deletion encompassing the reverse tran-
scriptase gene and part of integrase, but contains all
other HIV-1 genes (Fig. 1B). This construct, or derivatives
containing each MA mutation, was transfected into HeLa
cells, and virus was collected and analyzed by immu-
noblotting using serum from an AIDS patient. Examina-
tion of Fig. 5 reveals that processing is not necessary
for Env association with particles as indicated by the Pr0
MA/ virus (PR0Dbal). However, the three MA mutantsFIG. 4. Mutant MA in viral particles. (A) Virus particles were immu-
were defective in the ability to acquire Env. Phosphorim-noblotted with serum from an AIDS patient as described under Materi-
age analysis was performed on viral proteins from sev-als and Methods and detected using enhanced chemiluminescence.
The Gag precursor (Pr55), capsid (p24), and matrix (p17) are indicated eral experiments and these data indicate that Env-gp
by arrows. (B) Virus was prepared as described under Materials and association with mutant virions was consistently reduced
Methods. Equal amounts of virus as determined by a p24 ELISA were to a level that was less than 20% that of particles withloaded on the gel. The protein was separated on a 15% SDS–PAGE
wild-type MA.gel and silver stained. The markers are indicated by arrows on the left
To determine whether the mutants were also deficientside of the gel (30 Kd, 21.5 Kd, and 14.3 Kd), and p17 (MA) and p24
(CA) are indicated by arrows on the right side of the gel. in the ability to acquire a heterologous retrovirus enve-
lope glycoprotein, the matrix mutants were transcomple-
mented with an amphotropic murine leukemia virus enve-
was performed on viral pellets using patient serum that lope expression construct SV-A-MuLV env (Page et al.,
recognized the MA protein (Fig. 4A). MA protein was 1990) (Fig. 1B). GB107 or the MA0 mutant constructs
detected for the MA29 mutant but was not detected in were transfected into HeLa cells along with SV-A-MuLV
the MA18,20,22 or MA32,33 viruses. To determine env. The resulting virus was then analyzed by Western
whether the protein was not recognized by the patient analysis using an antibody to detect the amphotropic
serum due to alteration of an epitope or whether the viral envelope. This approach indicated that this heterologous
protein was actually absent, viral protein was separated Env-gp was efficiently incorporated into particles and that
on a SDS–PAGE gel and the proteins were detected the Env-gp/p24 ratio was similar (data not shown). Since
by silver staining (Fig. 4B). This analysis indicated that the mutants were able to acquire the amphotropic enve-
MA32,33 and MA18,20,22 particles contain MA at levels lope we investigated the ability of the pseudotyped virus
comparable to those of the wild type. The slightly altered to replicate over one round of replication. Wild-type or
mobility of the MA18,20,22 and MA32,33 MA is probably mutant virus was expressed along with amphotropic Env
due to amino acid substitutions in these mutants. in HeLa cells. Three days later the virus was harvested
The encapsidation sequence of HIV-1 has been re- and used to infect CD4/ LTR/b-gal indicator cells. This
ported to extend into the gag gene (Rhee and Hunter, analysis indicated that the three mutants were still defec-
1990; Buchschacher and Panganiban, 1992; Berkowitz et tive in replication. However, MA29 and MA18,20,22 were
al., 1993; Berkowitz and Goff, 1994). Thus, mutations in
the portion of the gag gene that encodes MA could alter
a cis-acting sequence necessary for encapsidation or
MA mutations could somehow interfere with encapsida-
tion in trans by altering the conformation of Gag. To deter-
mine whether the mutant viruses efficiently encapsidate
viral RNA, RNA was isolated from equivalent amounts of
virus, and hybridization analysis was performed using a
pol-specific probe. This analysis indicated that encapsi-
dation was similar for the mutants and wild-type virus
(data not shown).
We next determined whether MA29, MA18,20,22, and
MA32,33 were defective in Env acquisition. Since
FIG. 5. Env incorporation into mutant MA particles. Virus was pre-MA18,20,22 and MA32,33 appeared to have a slight ef-
pared as described under Materials and Methods. The blot was probedfect on proteolytic processing of Gag, and since we
with serum from an AIDS patient and protein was visualized using a
wanted to compare Env-gp acquisition without the com- 35S-conjugated antibody. The wild-type control (Pr0Dbal) was loaded
plication of differential Gag processing in parallel sam- in serial twofold dilutions as indicated. The envelope glycoprotein
gp120 and Gag Pr55 are indicated.ples, we analyzed the mutants in a protease minus (Pr0)
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TABLE 3 reverse transcription of MA29 was reduced to a level of
about 40% that of wild-type virus. Thus, although mutationInfectivity of MA Mutants Pseudotyped with Amphotropic
of position 29 does affect a step(s) in replication prior toMurine Leukemia Virus Env
reverse transcription, the data are consistent with a de-
Virus with fect in an additional replication step following reverse
amphotropic Relative titer transcription but prior to provirus formation. Table 4 sum-
envelope { SDa
marizes the properties of MA18,20,22, MA32,33, and
MA29.GB107 100 { 15
MA18,20,22 4 { 4
MA29 17 { 21
DISCUSSIONMA32,33 0.04 { 0.03
Our results indicate that individual mutations in MAa Virus was complemented with SV-A-MuLV envelope. The transfec-
can have pleiotropic effects on replication, simultane-tions were done in duplicate and the infections were performed on
CD4/ LTR/b-gal indicator cell as described under Materials and Meth- ously reducing diverse events including Env-gp acquisi-
ods. The mutant viruses were normalized to wild type in each experi- tion, viral entry/uncoating, and a step following reverse
ment. The titer of wild-type virus was between 5 1 104 and 7 1 105 b- transcription. All six mutated amino acids in MA18,20,22,
gal-inducing units per milliliter with a median of 2 1 105. The data from
MA29, and MA32,33 are highly conserved in each of thesix experiments are shown.
seven distinct HIV-1 subtypes (Louwagie et al., 1993) and
the tyrosine at amino acid 29 is absolutely conserved.
The three-dimensional structure of MA has recently beenless severely affected than when they had been comple-
mented by HIV-1 Env (Table 3). solved using NMR (Matthews et al., 1994). It is interesting
to note that amino acids 18, 20, 22, 26–28, 30, 32, andTo determine whether the pseudotyped MA mutants
were defective in virus entry or some event immediately 95 are all on the solvent-exposed side of a b-sheet.
These amino acids may interact with the inner face offollowing entry we performed an assay to accurately
measure the immediate products of reverse transcrip- the membrane, allowing for interaction with acid phos-
pholipids (Matthews et al., 1994; Zhou et al., 1994), whichtion. Equal amounts of virus, pseudotyped with ampho-
tropic Env, were used to infect HeLa cells. Eight hours would strengthen Gag–membrane interaction. Alterna-
tively, these amino acids might be in a position to interactafter infection cell lysates were collected and QC-PCR
was performed to measure the amount of intracellular with the envelope glycoprotein of the virus. We have
mutated all but one of the amino acids predicted to formviral DNA (Fig. 6). As a control for contamination from
transfected DNA, wild-type virus lacking Env was used the solvent side of this b-sheet. Amino acids 26, 27, and
30 were changed from lysine to glutamic acid and hadin parallel with the pseudotyped virus. We also incorpo-
rated a low-temperature control in which virus–cell inter- little effect on replication. Amino acid 95 was changed
from a lysine to an isoleucine and together with two otheraction was allowed to take place but Env–membrane
fusion was blocked. Two primer pairs were used to de- mutations also had little effect on replication. However,
changing amino acids 18, 20, 22, 32, or 33 from basic totect the reverse-transcribed products. The first pair (R –
L) was designed to detect full-length, or nearly full-length, uncharged drastically reduced infectivity. Other muta-
tions within the first 32 amino acids also decreased theproducts of reverse transcription; one primer is from the
R region of the LTR and the other primer is distal to the efficiency of virion production and caused incorrect tar-
geting of the Gag precursor protein to intracellular mem-primer-binding site (Fig. 6A). The second primer pair (R –
U5) was chosen to detect minus-strand strong stop DNA branes (Yuan et al., 1993). This supports the idea that at
least some of these basic residues are important forand all subsequent products of reverse transcription;
these primers are capable of amplifying a region within correct and stable membrane interaction. These effects
could also account for the slightly reduced level of virionthe R and U5 regions of the LTR.
Using this approach it was evident that, as expected, production observed with MA18,20,22 and MA32,33.
Freed and co-workers previously analyzed the replica-wild-type virus is able to enter the cell and reverse tran-
scribe its RNA at levels well above background (Figs. tion proficiency of a battery of mutants in the MA (Freed
et al., 1994). One of those mutants contained an R-to-L6B –6D). However, at 8 hr after infection it was evident
that there was about 10-fold less full-length viral DNA substitution at amino acid position 20, and that mutant
replicated efficiently. In MA18,20,22 position 20 containscompared to the initial minus-strand product(s) of reverse
transcription (Figs. 6C and 6D). In the case of MA18,20,22 an R-to-I substitution. Since the nature of the substituting
amino acid at position 20 is very similar for these mu-and MA32,33 entry was reduced to levels near back-
ground with both primer pairs. Thus, replication of tants, the phenotype of MA18,20,22 is most likely due to
substitution at positions 18 or 22. Similarly, one of theMA18,20,22 and MA32,33 was blocked even prior to syn-
thesis of minus-strand, strong stop DNA. Interestingly, mutants in that study contained a K-to-A substitution at
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FIG. 6. Quantitative competitive PCR of intracellular products of reverse transcription. (A) The primer pair R–U5 is complementary to a segment
of minus-strand strong stop DNA and that segment would also be present on all subsequent reverse transcription products. The ‘‘R–L’’ primer pair
would amplify viral DNA that is full length or nearly full length. pCC91 has a 41-nucleotide deletion within the amplified region. (B) QC-PCR using
the R–L primer pair. All cell lysates (templates) were prepared as described under Materials and Methods following infection of cells with equivalent
physical titers of virus (0.3 ng p24 as determined by an ELISA against the capsid protein). In each reaction, 4 ml of cell lysate was amplified along
with the indicated number of molecules of competitor DNA (CC91) using reaction conditions described under Materials and Methods. To determine
the number of template molecules present in a constant volume of cell lysate, the relative amounts of template and competitor were measured by
phosphorimage analysis. ‘‘GB107 07’’ indicates GB107 pseudotyped with amphotropic Env that was allowed to bind to the cells at 07. (C) Relative
amounts of minus-strand strong stop DNA following infection with wild-type virus and MA mutants. The number of copies of viral DNA was
determined using QC-PCR as described under Materials and Methods. The data were derived from four separate experiments. In each experiment
the number of molecules present following infection with wild-type virus was normalized to 100. On average, there were approximately 25,000
minus-strand strong stop molecules/4 ml sample of lysate from cells infected with GB107. (D) Relative amounts of full-length viral DNA following
infection with wild-type virus and MA mutants. The data were derived from four separate experiments including that shown in (B). In each experiment
the number of molecules present following infection with wild-type virus was normalized to 100. On average, there were about 2800 full-length viral
DNA molecules/4 ml sample of lysate from cells infected with GB107.
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FIG. 6—Continued
position 32 and was replication proficient although repli- that the replication-defective phenotype of MA32,33 is
due to the mutation at position 33.cation appeared to not be as efficient as that in wild type.
However, since the mutation at position 32 in MA32,33 It is possible that in the three mutants deficient in Env
acquisition there is specific abrogation of a direct MA–is a K-to-I substitution, we cannot distinguish between
the possibility that an alanine residue is tolerated at posi- Env interaction. This possibility seems plausible in light
of the 3-D structure of MA, which, as described above,tion 32 but an isoleucine residue is not or the possibility
indicates that the amino acids 18, 20, 22, and 32 are on
the solvent-exposed side of the protein and thus may be
TABLE 4 free to interact with Env. However, each of the three
replication-defective MA mutants studied here also ap-Summary of the Phenotypes of MA18,20,22 MA29, and MA32,33
pears to alter the conformation of Gag, as evidenced
WT MA18,20,22 MA29 MA32,33 by less efficient processing of Pr55 in particles and the
accumulation of intracellular p25. Therefore, it is possible
Relative infectivity 1.0 0.004 0.027 0.001
that the lack of Env in the mutants may not be due to aRelative virus production 1.0 0.23 0.99 0.23
direct effect on MA–Env interaction but may instead beIntracellular p24/p55 1.0 0.40 1.1 0.61
p24/p55 in virions 1.0 0.39 1.2 0.20 an indirect effect resulting from alteration of the global
Relative infectivity of structure of the gag polyprotein.
pseudotyped particles 1.0 0.004 0.17 0.0004 Interestingly, the MA mutants, while defective in HIV-1
Relative incorporation of
Env incorporation, are able to incorporate a heterologousMo-MuLV Env-gp
retroviral Env at wild-type levels. In fact most of MA can(Env/p24) 1.0 1.2 0.9 0.9
Minus-strand strong be deleted without affecting the ability of the virus to be
stop DNA synthesis 1.0 0.03 0.33 0.04 pseudotyped with amphotropic MuLV Env (Yuan et al.,
Full-length DNA 1993). It is unclear whether pseudotyping normally in-
synthesis 1.0 0.12 0.18 0.03
volves specific interaction between the capsid and heter-
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syndrome-associated retrovirus in human and nonhuman cells trans-ologous Env. MuLV incorporates its own Env with speci-
fected with an infectious molecular clone. J. Virol. 59, 284–291.ficity (Suomalainen and Garoff, 1994). In the case of HIV-
Alin, K., and Goff, S. P. (1996). Amino acid substitutions in the CA protein
1 MA mutants, it seems unlikely that there is a direct of Moloney murine leukemia virus that block early events in infection.
specific interaction between the viral core and MuLV env. Virology 222, 339–351.
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even the initial product of reverse transcription (minus- J. Virol. 67, 7190–7200.
strand, strong stop DNA) was greatly reduced, indicating Bryant, M., and Ratner, L. (1990). Myristoylation-dependent replication
and assembly of human immunodeficiency virus 1. Proc. Natl. Acad.that these mutations affect a step prior to the initiation
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